Garenoxacin
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319504

CAS#: 194804-75-6

Description: Garenoxacin is a novel oral des-fluoro(6) quinolone with potent antimicrobial activity against common respiratory pathogens, including resistant strains. It has favourable pharmacokinetic profiles for maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC), with good penetration into sputum and otorhinolaryngological tissues. In clinical studies, the efficacy of Garenoxacin ranged from 92% to 96% in patients with bacterial pneumonia, mycoplasma pneumonia, chlamydial pneumonia and acute bronchitis. Garenoxacin is very effective in treating patients with upper and lower respiratory tract infections.


Chemical Structure

img
Garenoxacin
CAS# 194804-75-6

Theoretical Analysis

MedKoo Cat#: 319504
Name: Garenoxacin
CAS#: 194804-75-6
Chemical Formula: C23H20F2N2O4
Exact Mass: 426.13911
Molecular Weight: 426.41981
Elemental Analysis: C, 64.78; H, 4.73; F, 8.91; N, 6.57; O, 15.01

Price and Availability

Size Price Availability Quantity
10.0mg USD 90.0 2 Weeks
25.0mg USD 150.0 2 Weeks
50.0mg USD 250.0 2 Weeks
100.0mg USD 450.0 2 Weeks
200.0mg USD 750.0 2 Weeks
500.0mg USD 1250.0 2 Weeks
1.0g USD 1950.0 2 Weeks
2.0g USD 2950.0 2 Weeks
5.0g USD 3950.0 2 Weeks
10.0g USD 4950.0 2 Weeks
Click to view more sizes and prices
Bulk inquiry

Synonym: BMS284756; BMS 284756; BMS-284756; Garenoxacin. tradename Geninax.

IUPAC/Chemical Name: 1-Cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

InChi Key: NJDRXTDGYFKORP-LLVKDONJSA-N

InChi Code: InChI=1S/C23H20F2N2O4/c1-11-15-5-2-12(8-13(15)9-26-11)16-6-7-17-19(21(16)31-23(24)25)27(14-3-4-14)10-18(20(17)28)22(29)30/h2,5-8,10-11,14,23,26H,3-4,9H2,1H3,(H,29,30)/t11-/m1/s1

SMILES Code: O=C(C1=CN(C2CC2)C3=C(C=CC(C4=CC5=C([C@@H](C)NC5)C=C4)=C3OC(F)F)C1=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 426.41981 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Yamagishi Y, Hagihara M, Hamada Y, Kimura Y, Imai H, Mikamo H. Pharmacokinetic study of garenoxacin in severe renal failure patients. Jpn J Antibiot. 2015 Jun;68(3):141-50. PubMed PMID: 26349115.

2: Hajare A, Gupta A, Patil S, Krishnaprasad K, Bhargava A. A prescription event monitoring study on the utility of garenoxacin, a newer fluoroquinolone in India. Int J Appl Basic Med Res. 2015 May-Aug;5(2):87-91. doi: 10.4103/2229-516X.157151. PubMed PMID: 26097813; PubMed Central PMCID: PMC4456900.

3: Tagawa M, Ochiai S, Nakamura Y, Sato A, Chinushi M. Secondly ECG recordings in the emergency room revealed Garenoxacin-induced abnormal QT interval prolongation in a patient with multiple syncopal attacks. Heart Vessels. 2015 May 29. [Epub ahead of print] PubMed PMID: 26022375.

4: Uni M, Yoshimi A, Yamazaki S, Taoka K, Shinohara A, Nannya Y, Nakamura F, Kurokawa M. Comparison of garenoxacin with levofloxacin as antimicrobial prophylaxis in acute myeloid leukemia. Jpn J Clin Oncol. 2015 Aug;45(8):745-8. doi: 10.1093/jjco/hyv071. Epub 2015 May 19. PubMed PMID: 25989991.

5: Vora A. Garenoxacin. J Assoc Physicians India. 2014 Jan;62(1):34-5. PubMed PMID: 25327090.

6: Hata A, Katakami N, Masuda Y, Takashima K, Takeshita J, Tanaka K, Kaji R, Fujita S, Ose T, Kitajima N. [Comparison of garenoxacin and levofloxacin for the prophylaxis of febrile neutropenia]. Gan To Kagaku Ryoho. 2014 Sep;41(9):1119-23. Japanese. PubMed PMID: 25248895.

7: Pukar MM, Hajare AL, Krishnaprasad K, Bhargava AI. Garenoxacin in Skin and Skin Structure Infections Sustained due to Road Traffic Accident. J Clin Diagn Res. 2014 Jun;8(6):HD01-3. doi: 10.7860/JCDR/2014/9066.4458. Epub 2014 Jun 20. PubMed PMID: 25121004; PubMed Central PMCID: PMC4129297.

8: Izumikawa K, Watanabe A, Miyashita N, Ishida T, Hosono H, Kushimoto S, Kohno S. Efficacy and safety of garenoxacin tablets on bacterial pneumonia: postmarketing surveillance in Japan. J Infect Chemother. 2014 Sep;20(9):549-57. doi: 10.1016/j.jiac.2014.05.003. Epub 2014 Jun 13. PubMed PMID: 24934887.

9: Izumikawa K, Watanabe A, Miyashita N, Ishida T, Hosono H, Kushimoto S, Kohno S. Efficacy and safety of garenoxacin tablets on clinically diagnosed atypical pneumonia: postmarketing surveillance in Japan. J Infect Chemother. 2014 Sep;20(9):541-8. doi: 10.1016/j.jiac.2014.05.002. Epub 2014 Jun 13. PubMed PMID: 24934886.

10: Fukuda Y, Furuya Y, Nozaki Y, Takahata M, Nomura N, Mitsuyama J. Therapeutic effects of garenoxacin in murine experimental secondary pneumonia by Streptococcus pneumoniae after influenza virus infection. Diagn Microbiol Infect Dis. 2014 Feb;78(2):168-71. doi: 10.1016/j.diagmicrobio.2013.11.003. Epub 2013 Nov 14. PubMed PMID: 24321356.

11: Kohno S, Yanagihara K, Yamamoto Y, Tokimatsu I, Hiramatsu K, Higa F, Tateyama M, Fujita J, Kadota J. Early switch therapy from intravenous sulbactam/ampicillin to oral garenoxacin in patients with community-acquired pneumonia: a multicenter, randomized study in Japan. J Infect Chemother. 2013 Dec;19(6):1035-41. doi: 10.1007/s10156-013-0618-5. Epub 2013 May 22. PubMed PMID: 23695232.

12: Miyake M, Oiso N, Yoshinaga E, Kawada A. Fixed drug eruption due to garenoxacin mesilate hydrate. Eur J Dermatol. 2013 Jan-Feb;23(1):111-2. doi: 10.1684/ejd.2012.1892. PubMed PMID: 23400227.

13: Schaumann R, Janssen E, Funke M, Stîngu CS, Genzel GH, Janssen M, Rodloff AC. In vitro activities of levofloxacin, gatifloxacin, moxifloxacin and garenoxacin against Bacteroides fragilis strains evaluated by kill kinetics. J Med Microbiol. 2013 Apr;62(Pt 4):576-81. doi: 10.1099/jmm.0.053280-0. Epub 2013 Jan 14. PubMed PMID: 23319309.

14: Takahata M, Sugiura Y, Shinmura Y, Fukuda Y, Nomura N. Bactericidal activity of garenoxacin against in vitro biofilm formed by nontypeable Haemophilus influenzae. J Infect Chemother. 2013 Jun;19(3):441-6. doi: 10.1007/s10156-012-0502-8. Epub 2012 Oct 23. PubMed PMID: 23089895.

15: Fukushima K, Nakatsubo M, Noda M, Uenami T, Hayama Y, Tsuruta N, Oniki S, Saito Y, Niju T, Ikeda T. Anaphylaxis due to intravenous levofloxacin with tolerance to garenoxacin. Intern Med. 2012;51(13):1769-72. Epub 2012 Jul 1. PubMed PMID: 22790143.

16: Nakatani M, Mizunaga S, Takahata M, Nomura N. Inhibitory activity of garenoxacin against DNA gyrase of Mycoplasma pneumoniae. J Antimicrob Chemother. 2012 Aug;67(8):1850-2. doi: 10.1093/jac/dks140. Epub 2012 Apr 24. PubMed PMID: 22532464.

17: Futakuchi N, Nakatani M, Takahata M, Mitsuyama J. In vitro antichlamydial activity of garenoxacin against Chlamydia trachomatis. J Infect Chemother. 2012 Aug;18(4):428-35. doi: 10.1007/s10156-011-0345-8. Epub 2011 Nov 25. PubMed PMID: 22113367.

18: Fukuda Y, Takahata M, Sugiura Y, Shinmura Y, Nomura N. In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae. Int J Antimicrob Agents. 2012 Feb;39(2):163-7. doi: 10.1016/j.ijantimicag.2011.09.021. Epub 2011 Nov 15. PubMed PMID: 22088660.

19: Ito M, Maruyama Y, Murono S, Wakisaka N, Kondo S, Hatano M, Nakanishi S, Miwa T, Yoshizaki T. Efficacy and safety of garenoxacin in the treatment of upper respiratory tract infections. Auris Nasus Larynx. 2012 Oct;39(5):512-8. doi: 10.1016/j.anl.2011.09.004. Epub 2011 Nov 9. PubMed PMID: 22078851.

20: Tanigawara Y, Nozawa K, Tsuda H. Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation. Eur J Clin Pharmacol. 2012 Jan;68(1):39-53. doi: 10.1007/s00228-011-1095-3. Epub 2011 Jul 28. PubMed PMID: 21796376; PubMed Central PMCID: PMC3249185.